Shift from Systemic to Site-Specific Memory by Tumor-Targeted IL-2

Journal of Immunology

Volumn 172, Issue 10, 2004, Pages 5843-5850

  Schrama, David ^a   Xiang, Rong ^b   Eggert, Andreas O ^a   Andersen, Mads Hald ^c   Pedersen, Lars Østergaard ^c   Kämpgen, Eckhart ^a   Schumacher, Ton N ^d   Reisfeld, Ralph R ^b   Becker, Jürgen C ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; PEPTIDE; TUMOR VACCINE; TYROSINASE RELATED PROTEIN 2;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; LUNG METASTASIS; MELANOMA; MELANOMA B16; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VACCINATION;

EID: 2442511020     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.10.5843     Document Type: Article

References (35)

1. Sprent, J., and C. D. Surh. 2002. T cell memory. Annu. Rev. Immunol. 20:551.
2. Tanchot, C., F. A. Lemonnier, B. Perarnau, A. A. Freitas, and B. Rocha. 1997. Differential requirements for survival and proliferation of CD8 naive or memory T cells. Science 276:2057.
3. + T cells. Immunol. Rev. 186:221.
4. Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708.
5. Masopust, D., and L. Lefrancois. 2003. CD8 T-cell memory: the other half of the story. Microbes Infect. 5:221.
6. Schluns, K. S., and L. Lefrancois. 2003. Cytokine control of memory T-cell development and survival. Nat. Rev. Immunol. 3:269.
7. Zinkernagel, R. M. 2003. On natural and artificial vaccinations. Annu. Rev. Immunol. 21:515.
8. Mocellin, S., C. R. Rossi, M. Lise, and F. M. Marincola. 2002. Adjuvant immunotherapy for solid tumors: from promise to clinical application. Cancer Immunol. Immunother. 51:583.
9. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
10. Marten, A., D. Flieger, S. Renoth, S. Weineck, P. Albers, M. Compes, B. Schottker, C. Ziske, S. Engelhart, P. Hanfland, et al. 2002. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol. Immunother. 51:637.
11. + progenitor-derived dendritic cell vaccine. Cancer Res. 61:6451.
12. Coulie, P. G., and P. Bruggen. 2003. T-cell responses of vaccinated cancer patients. Curr. Opin. Immunol. 15:131.
13. Eggert, A. O., J. C. Becker, M. Ammon, A. D. McLellan, G. Renner, A. Merkel, E. B. Brocker, and E. Kampgen. 2002. Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture. Eur. J. Immunol. 32:122.
14. Haraguchi, M., S. Yamashiro, A. Yamamoto, K. Furukawa, K. Takamiya, K. O. Lloyd, and H. Shiku. 1994. Isolation of GD3 synthase gene by expression cloning of GM3 α-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody. Proc. Natl. Acad. Sci. USA 91:10455.
15. Gillies, S. D., E. B. Reilly, K. M. Lo, and R. A. Reisfeld. 1992. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc. Natl. Acad. Sci. USA 89:1428.
16. Becker, J. C., J. D. Pancook, S. D. Gillies, K. Furukawa, and R. A. Reisfeld. 1996. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med. 183:2361.
17. Haanen, J. B., M. G. van Oijen, F. Tirion, L. C. Oomen, A. M. Kruisbeek, F. P. A. Vyth-Dreese, and T. N. Schumacher. 2000. In situ detection of virus- and tumor-specific T-cell immunity. Nat. Med. 6:1056.
18. Taguchi, T., J. R. McGhee, R. L. Coffman, K. W. Beagley, J. H. Eldridge, K. Takatsu, and H. Kiyono. 1990. Detection of individual mouse splenic T cells producing IFN-γ and IL-5 using the enzyme-linked immunospot (ELISPOT) assay. J. Immunol. Methods 128:65.
19. Niethammer, A. G., R. Xiang, J. M. Ruehlmann, H. N. Lode, C. S. Dolman, S. D. Gillies, and R. A. Reisfeld. 2001. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res. 61:6178.
20. Ochsenbein, A. F. 2002. Principles of tumor immunosurveillance and implications for immunotherapy. Cancer Gene Ther. 9:1043.
21. Engelhard, V. H., T. N. Bullock, T. A. Colella, S. L. Sheasley, and D. W. Mullins. 2002. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol. Rev. 188:136.
22. Ramirez-Montagut, T., M. J. Turk, J. D. Wolchok, J. A. Guevara-Patino, and A. N. Houghton. 2003. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 22:3180.
23. Sprent, J. 2002. T memory cells: quality not quantity. Curr. Biol. 12: R174.
24. Manjunath, N., P. Shankar, J. Wan, W. Weninger, M. A. Crowley, K. Hieshima, T. A. Springer, X. Fan, H. Shen, J. Lieberman, and U. H. von Andrian. 2001. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J. Clin. Invest. 108:871.
25. + T cells. J. Exp. Med. 194:953.
26. Masopust, D., V. Vezys, A. L. Marzo, and L. Lefrancois. 2001. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291:2413.
27. Mackay, C. R., and U. H. von Andrian. 2001. Immunology: memory T cells-local heroes in the struggle for immunity. Science 291:2323.
28. Becker, J. C., N. Varki, S. D. Gillies, K. Furukawa, and R. A. Reisfeld. 1996. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J. Clin. Invest. 98:2801.
29. Straten, P. T., P. Guldberg, T. Seremet, R. A. Reisfeld, J. Zeuthen, and J. C. Becker. 1998. Activation of preexisting T cell clones by targeted interleukin 2 therapy. Proc Natl. Acad. Sci. USA 95:8785.
30. Wherry, E. J., V. Teichgraber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. von Andrian, and R. Ahmed. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4:225.
31. Naftzger, C., Y. Takechi, H. Kohda, I. Hara, S. Vijayasaradhi, and A. N. Houghton. 1996. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc. Natl. Acad. Sci. USA 93:14809.
32. + T lymphocytes. Proc. Natl. Acad. Sci. USA 96:2982.
33. Phan, G. Q., P. Attia, S. M. Steinberg, D. E. White, and S. A. Rosenberg. 2001. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 19:3477.
34. Becker, J. C., P. Guldberg, J. Zeuthen, E. B. Brocker, and P. T. Straten. 1999. Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J. Invest. Dermatol. 113:1033.
35. Bondanza, A., V. S. Zimmermann, G. Dell'Antonio, E. Dal Cin, A. Capobianco, M. G. Sabbadini, A. A. Manfredi, and P. Rovere-Querini. 2003. Cutting edge: dissociation between autoimmune response and clinical disease after vaccination with dendritic cells. J. Immunol. 170:24.